Kidney Week

Abstract: PO2258

Time on Patiromer Therapy and Impact on Serum Potassium Levels in Real-World German CKD Patients

Session Information

• CKD: Associations and Electrolytes
  November 04, 2021 | Location: On-Demand, Virtual Only
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Roberto Pecoits-Filho, MD, PhD, FASN

• Muenz, Daniel G., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Daniel G. Muenz,

• McCullough, Keith, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Keith McCullough,

• Massy, Ziad, Centre Hospitalier Universitaire Ambroise Pare, Mons, Wallonie, Belgium

Ziad Massy,

• Bieber, Brian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Brian Bieber,

• Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Bruce M. Robinson,

• Fliser, Danilo, Universitatsklinikum des Saarlandes und Medizinische Fakultat der Universitat des Saarlandes, Homburg, Saarland, Germany

Danilo Fliser,

• Golden, John, Vifor Fresenius Medical Care Renal Pharma, Munich, Spain

John Golden,

• Moreno Quinn, Carol Patricia, Vifor Pharma, Glattbrugg, Switzerland

Carol Patricia Moreno Quinn,

• Calice-Silva, Viviane, Pro-Kidney Foundation, Joinville, Brazil

Viviane Calice-Silva,

• Ramirez de Arellano, Antonio, Vifor Pharma, Glattbrugg, Switzerland

Antonio Ramirez de Arellano,

• Reichel, Helmut, Nephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany

Helmut Reichel,

Background

Hyperkalemia (HK) (serum K>5.0 mEq/L) is a frequent condition in patients with chronic kidney disease (CKD) associated with high morbidity and mortality and it is a common reason for RAASi discontinuation and dose limitation. Patiromer is a non-absorbed, sodium-free, potassium (K) binder that has been shown to chronically reduce serum K in patients with HK, enabling RAASi therapy, which is supported by randomized trial evidence in CKD patients. Data on patiromer use in patients with moderate-to-advanced CKD in the real-world setting in Europe is lacking. We describe time to discontinuation and changes in serum K levels among CKD stage 3-5 patients starting patiromer using 2018-21 data from German participants in CKD Outcomes and Practice Patterns Study (CKDopps).

Methods

Duration of patiromer use was estimated by Kaplan-Meier curve, starting at patiromer initiation and censoring for death, dialysis, transplant, or loss of follow-up. Serum K levels are described as mean/median at the baseline and in ranges of 1-30, 31-90 and 91-180 days during the follow up, restricted to patients remaining on patiromer.

Results

Patiromer use was limited to 34 of 90 clinics. We identified 155 Patiromer users, 131 with K measurements at baseline and 110 with at least one follow-up value. 79% of patiromer users were CKD stage 4/5, v. 28% of non-patiromer users in the sample. A large proportion (95%) of patiromer users stayed on treatment past 1 month, with 53% of surviving users continuing for over a year (Fig 1A). Mean serum K levels decreased after patiromer initiation and remained stable under treatment during follow-up (up to 180 days) (Fig 1B).

Conclusion

Most patients were not observed to discontinue patiromer prior to one year after initiation. Mean levels of serum K were lower after patiromer initiation and remained stable during the follow-up period.

Funding

• Commercial Support –